Histone deacetylase inhibitors (HDACi), like trichostatin A, show promise in preclinical models by reducing cyst growth and preserving renal function by enhancing acetylation and suppressing CFTR-mediated fluid secretion [181]. The gene discussed is CFTR; the disease is cyst.